Lumida
/BIO
⌘K
Bio Rad Laboratories Inc

Bio Rad Laboratories Inc

BIO
$369.32USD↑+0.15%+0.57 today

MARKET CAP

9.9B

P/E (TTM)

63.6x

FWD P/E

—

DAY RANGE

$369 – $374

52W RANGE

$237
$396

AI Summary

Stalk
Sell NowMedium

Following the recent Bearish Pivot Point and decisive failure beneath the 9 and 20 EMAs, BIO has entered a Stage 4 decline. Medium-term directional asymmetry is clearly bearish as price rejects the sloped EMAs with no oversold exhaustion, prompting immediate bearish engagement. Short-term timing is favorable with a rejection at the 20 EMA, while the long-term uptrend on the 200-day SMA remains intact but currently overshadowed by near-term weakness. Execution via a sell into the 20 EMA resistance zone is advised.

  • ↑Q2 2026 adj. EPS $2.62 on $651 M revenue topped consensus
  • ↑Digital PCR instrument sales grew over 20% year-over-year
  • ↓Life Science revenue slipped 4.1% YoY to $252 M amid academic market softness
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Bio-Rad Laboratories (NYSE: BIO) is a leading player in the life sciences and clinical diagnostics sectors, providing innovative solutions for research and clinical laboratories. The company is positioned strongly in two key segments: Life Science, which encompasses biotechnology and pharmaceutical applications, and Clinical Diagnostics, focused on disease diagnosis and treatment monitoring. Bio-Rad is at the forefront of advancements such as digital PCR technology and is navigating a dynamic healthcare landscape aimed at improving operational efficiency.

Bull says

  • ↑Q2 2026 adj. EPS $2.62 on $651 M revenue topped consensus
  • ↑Digital PCR instrument sales grew over 20% year-over-year
  • ↑Restructuring to deliver $30–35 M in annual cost savings
  • ↑Stock hit 52-week high $365.68, up 24% over past year
  • ↑Repurchased $32 M of shares (110 K shares) in Q2
  • ↑High earnings yield and positive analyst revisions support upside

Bear says

  • ↓Life Science revenue slipped 4.1% YoY to $252 M amid academic market softness
  • ↓China sales down high-teens, highlighting geopolitical risk
  • ↓Non-GAAP operating margin fell to 12.5% despite 53.1% gross margin
  • ↓Currency-neutral full-year revenue guidance trimmed to ‑3%/+0.5%
  • ↓Negative growth and profitability factors limit expansion
  • ↓Low institutional ownership and weak dividend yield deter buyers

Investment themes with BIO

Medical Devices↑ +0.44%

Devices and instruments for medical treatment

MEDP · RDNT · OPCH

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 05-04-2025neutral

Transcript signals

Bull points

  • We're not seeing that we're losing customers. We're maintaining share. In fact, we still believe we are winning share as we called out in the script.
  • There's some strength in clinical diagnostics that looks good to us right now. which kind of keeps us within our guide range overall.
  • we view the franchise recovering in line with market recovery as we go through the remaining quarters in the year.

Bear points

  • The first quarter of 2024 reflected a continuation of the same macroeconomic and market trends we had experienced in 2023 in the Biotech and Biopharma segments as well as China and Russia.
  • our Life Science Group was in line with expectations and presented a soft quarter sales with a year-over-year decline which also reflected a tough comparison from Q1 of '23.
  • Our Life Science business experienced double-digit declines, both across our Core and Bioprocessing product families.
Read full transcript analysis ›